Friday, August 8, 2025

Hindustan Zinc to consider issuance of NCDs in March 10 meeting

Date:

Vedanta Group firm Hindustan Zinc Ltd on Wednesday (March 5) said it has scheduled a Committee of Directors meeting on March 10, 2025, to evaluate fundraising through the issuance of listed non-convertible debentures (NCDs) on a private placement basis, subject to market conditions.”…we hereby inform you that a meeting of the committee of directors of the Company (Committee) is scheduled to be held on Monday, March 10, 2025, inter alia, to consider and evaluate proposals for raising funds through the issue of listed non-convertible debentures on private placement basis, subject to market conditions,” Hindustan Zinc said in a regulatory filing.
The proposed issuance will be within the company’s borrowing limits and will require necessary approvals from stock exchanges and regulatory authorities. This follows a board resolution passed on January 28, 2025, authorising the company to explore debt-raising options.
Also Read: Hindustan Zinc OFS: Government plans to sell 2.5% stake in Vedanta Unit
“The proposed issuance shall be subject to the borrowing limits of the Company and any necessary approvals from stock exchanges and other regulatory/governmental authorities, as may be required. This proposal follows the resolution passed by the Board of Directors at its meeting held on January 28, 2025,” it added.Hindustan Zinc posted a net profit of ₹2,678 crore, exceeding the CNBC-TV18 poll estimate of ₹2,479 crore. This represents a significant growth of 32% year-on-year (YoY) compared to ₹2,028 crore in the same quarter last year.

Revenue stood at ₹8,614 crore, beating the poll forecast of ₹8,390 crore and recording a YoY growth of 17.8% from ₹7,310 crore. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) came in at ₹4,499 crore, ahead of the CNBC-TV18 estimate of ₹4,349 crore.

Also Read: Hindustan Zinc CEO expects price stability in early 2025

Shares of Hindustan Zinc Ltd ended at ₹411.35, up by ₹15.95, or 4.03%, on the BSE.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Access Denied

Access Denied You don't have permission to access "...

Zepto launches 10-minute pharmacy delivery in Mumbai, Bengaluru, Delhi NCR and Hyderabad

Zepto has officially entered the e-pharmacy segment with the...

Reliance Retail writes off Dunzo investment

Reliance Retail has written off its investment of nearly...

Indian drugmakers face uncertainty as Trump threatens steep tariffs and price cuts

US President Donald Trump’s renewed push to slash drug...